AUTHORS
Nowah Afangbedji, PhD, Hansen Tao2, Ishaan Vaswani, MS, BA3, Freja Kjellaug Amalia Ekman, BSc, MPhil4, Sridhar Selvaraj5, Ludwig Schmiderer6, Dick Nchang, BA7, Matthew Hebden Porteus, MD, PhD8
AFFILIATIONS
1 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
ABSTRACT
Background:
β-Hemoglobinopathies are among the most common monogenic disorders worldwide. Although sickle cell disease results from a single pathogenic HBB variant, β-thalassemia encompasses >300 disease-causing HBB variants, creating a major challenge for mutation-specific gene-editing strategies. We developed a mutation-agnostic approach that replaces endogenous HBB with a functional β-globin cassette and couples gene correction to erythroid-selective expansion of edited progeny.
Methods:
Human CD34+ hematopoietic stem and progenitor cells (HSPCs) were engineered ex vivo using CRISPR-Cas9 and AAV6-mediated homology-directed repair (HDR). A hybrid β-globin cassette (HybHBB), comprising HBB exons 1–3 and heterologous γ-globin introns, was targeted to the endogenous HBB locus either alone or linked to a truncated erythropoietin receptor (tEPOR) designed to confer an erythroid-selective proliferative advantage. Editing efficiency, erythroid differentiation and expansion, p53 pathway activation, and colony-forming capacity were evaluated across multiple donors. Engineered HSPCs were transplanted into immunodeficient mice (n=5, N=25) to assess engraftment, multilineage hematopoiesis, and persistence of the therapeutic cassette. Translational activity was evaluated in patient-derived HSPCs representing three distinct β-thalassemia genotypes: IVS-II-654C>T, c.316-197C>T/c.-78A>G, and CD41-42/IVS-II-1G>A.
Results:
HybHBB-tEPOR conferred more than 2-fold erythroid expansion advantage compared with HybHBB alone and drove approximately 4-fold enrichment of HDR-edited alleles during erythroid differentiation, increasing edited allele frequencies from 20% after editing to as high as 80% in erythroid progeny. Robust enrichment was maintained at low AAV6 multiplicities of infection (MOI 300–650), conditions associated with reduced p53 stress-response activation. Both HybHBB and HybHBB-tEPOR rescued β-globin deficiency following endogenous HBB disruption, while edited HSPCs retained colony-forming capacity. At 17 weeks after transplantation, engineered HSPCs supported durable multilineage human hematopoiesis, with mean human CD45+ chimerism reaching up to 74.7% ± 4.8% in bone marrow, 45% ±11% in spleen, and 55.1 ±21.2% in peripheral blood. Importantly, across genetically distinct β-thalassemia patient-derived HSPCs, the platform restored adult hemoglobin production, increasing HbA from 6% to as high as 82% following erythroid differentiation.
Conclusions:
Mutation-agnostic HBB replacement coupled to erythroid-selective expansion converts moderate initial editing into a highly enriched population of functionally corrected erythroid cells while preserving HSPC progenitor function and in vivo engraftment. By achieving robust HbA restoration across genetically distinct β-thalassemia samples at low vector doses, HybHBB-tEPOR provides a potentially scalable, genotype-independent therapeutic strategy for both sickle cell disease and β-thalassemia.
DISCLOSURES
Nowah Afangbedji, PhD: No relevant conflicts of interest to declare.